Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP2 | P08253 | 14/20 | 0.79 |
| ▸ | MMP9 | P14780 | 13/20 | 0.79 |
| ▸ | MMP8 | P22894 | 13/20 | 0.79 |
| ▸ | MMP1 | P03956 | 6/20 | 0.65 |
| ▸ | FCER2 | P06734 | 4/20 | 0.65 |
| ▸ | MMP7 | P09237 | 4/20 | 0.59 |
| ▸ | MMP3 | P08254 | 3/20 | 0.59 |
| ▸ | MMP13 | P45452 | 2/20 | 0.59 |
| ▸ | MMP12 | P39900 | 1/20 | 0.59 |
| ▸ | IDE | P14735 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29379670 | 1.00 | MMP2 (0.79) | MMP2MMP9MMP8MMP1FCER2 | |
| SCHEMBL13274328 | 1.00 | MMP2 (0.79) | MMP2MMP9MMP8MMP1FCER2 | |
| SCHEMBL29730834 | 1.00 | MMP2 (0.79) | MMP2MMP9MMP8MMP1FCER2 | |
| SCHEMBL12561524 | 1.00 | MMP2 (0.79) | MMP2MMP9MMP8MMP1FCER2 | |
| SCHEMBL1847906 | 1.00 | MMP2 (0.79) | MMP2MMP9MMP8MMP1FCER2 | |
| SCHEMBL13478923 | 1.00 | MMP2 (0.79) | MMP2MMP9MMP8MMP1FCER2 | |
| SCHEMBL8858285 | 0.92 | MMP2 (0.81) | MMP2MMP9MMP8MMP1FCER2 | |
| SCHEMBL8858286 | 0.91 | MMP2 (0.77) | MMP2MMP9MMP8MMP1FCER2 | |
| SCHEMBL314933 | 0.91 | MMP9 (0.81) | MMP2MMP9MMP8MMP1FCER2 | |
| SCHEMBL8858284 | 0.90 | MMP2 (0.89) | MMP2MMP9MMP8MMP1FCER2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100168089-A1 | UTILIZATION OF TACE INHIBITORS FOR THE TREATMENT OF ACNE | GALDERMA RESEARCH & DEVELOPMENT (FR) | 2010-07-01 | — | — | US | disclosed |
| US-5629285-A | Inhibitors of TNF-α secretion | IMMUNEX CORPORATION (US) | 1997-05-13 | — | — | US | disclosed |
| EP-0715619-A4 | INHIBITORS OF TNF-ALPHA SECRETION | IMMUNEX CORP (US) | 1997-03-19 | — | — | EP | disclosed |
| US-5594106-A | Inhibitors of TNF-α secretion | IMMUNEX CORPORATION (US) | 1997-01-14 | — | — | US | disclosed |
| EP-0715619-A1 | INHIBITORS OF TNF-ALPHA SECRETION | IMMUNEX CORPORATION (US) | 1996-06-12 | — | — | EP | disclosed |
| WO-1995006031-A1 | INHIBITORS OF TNF-ALPHA SECRETION | IMMUNEX CORPORATION (US) | 1995-03-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100168089-A1 | UTILIZATION OF TACE INHIBITORS FOR THE TREATMENT OF ACNE | MMP17, MMP25, TIMP3 | MMP2 7/4885MMP9 29/4885MMP8 6/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.